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                                                                                                                       Introduction 
Pseudomonas aeruginosa infection of a dermal wound can cause life threatening septicaemia, especially in humans and animals with compromised 
immunity (eg AIDS, organ recipients, burns patients).  Most clinical strains produce multiple virulence factors (VF) to facilitate the colonisation, 
destruction and penetration of the host1,2.  ETA and elastase digest collagen, elastin and disrupt cell-to-cell junctions3,4,5, & we are investigating how 
P.aeruginosa utilises these two  of its significant virulence factors to penetrate the circulatory system of the host.   
Mouse experiments 
Mice were implanted with a full thickness skin 
chamber  on day 0 ,(Figure 4)6.  On  day 1 and day 8,  
mouse skin chambers were either given 1 unit of 
elastase in phosphate buffered saline (PBS) or PBS 
alone.  Following  an overnight in-vivo incubation, 
the chambers were evacuated by pipette and 20mg of 
a 40KDa fluorescently labeled dextran (Invitrogen) 
was aliquoted to  each skin chamber. 5ml samples 
were taken from each skin chamber over the 
following 6 hrs , diluted in PBS and  the  
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Figure 3 :  Chromatogram  of protein separation of 
concentrated culture supernatant on DEAE sepharose 
(black line).  Elastase activity of fractions selected from  
the centre of elution peaks using Elastin Congo Red 
assay (purple line). SDS-PAGE analysis of fractions 31-34 
showing pure 33KDa elastase product (insert). 
                                                                              Previous results 
In previous experiments we have found:- 
•   the level of ETA in wound exudates are about 8 X times higher in mice treated with 
cyclophosphamide (CP) compared to normal mice (Figure 1), even though both groups had 
the same bacterial load in the chamber.      
•  CP reduced the concentration of leukocytes in wound exudates (Figure 2).  These mice, 
with reduced leukocytes and increased ETA levels, developed septicaemia. 
Hypothesis & aims 
Septacaemia is due to the increased level of VFs in the wound exudate, particularly  ETA & elastase, and this makes the tissue in the wound more 
permeable to penetration by P.aeruginosa.   Our aims are to compare the levels of elastase in normal and CP (immonosuppressed) treated mice, & to 
investigate the effect of purified P.aeruginosa elastase on the permeability of host tissue in a dermal wound using a fluorescently labelled 40 KDa marker.   
Purification of elastase 
P.aeruginosa  elastase  was purified  from a 
culture of strain PA01.  The  culture volume 
was reduced, buffer exchanged in 5mM 
Tris-HCl on a 10MWCO Amicon filter, 
loaded on a DEAE sepharose  column and 
eluted with  increasing NaCl concentration.  
Elastase positive fractions were identified 
using the elastin congo red assay (Figure 3).   
The  enzymatic activity of the purified 
product was  quantified  using  the DQ 
elastin assay (Invitrogen).  
Materials & Methods 
Figure 4 :  An anaesthetised mouse 
with a skin chamber implanted 
through a full thickness incision.  The 



















































hours after dextran added to chamber 













































Figure 1 :  Total volume of exudate recovered from the skin 
chamber of  mice 9 days after implantation.  Mice received 1U 
of elastase or PBS delivered to the skin chamber 18 hours prior 


























days after chamber implantation 
CP P.aeruginosa 
Figure 2 :  Concentration of viable leukocytes in skin chamber of 
mice challenged with P.aeruginosa.  One group of mice were given 
200mg/kg of cyclophosphamide 4 days after the skin chamber was 
implanted (dotted line).  Both groups received 3000 cfu of 
P.aeruginosa delivered to the chamber on day 5.  The skin chamber 
was evacuated by micro-pipette each day and viable leukocytes 
were counted in a counting chamber. +/- sd, n=5/group. 
Figure 5 :  Elastase activity in wound exudates of 
normal and CP treated mice infected with 
P.aeruginosa.  Elastase activity was estimated 
two days after infection using an Elastin DQ kit 
(Invitrogen). N=5/group.+/- sd. 
Figure 8 :  Wound exudates from skin chambers collected 
18hours after treatment with (a) PBS and (b) elastase on day 
8.  Elastase treated mice had increased exudate volume and 




Figure 7 :  Total volume of exudate 
recovered from the skin chamber of  mice 
2 & 9 days after implantation.  Mice 
received 1U of elastase or PBS delivered to 
the skin chamber 18 hours prior to exudate 
collection.+/- sd, n=5/group. 
Figure 6 :  Comparison of 40KDa dextran 
marker concentrations in the skin 
chambers of mice which had been treated 
with elastase one day after chamber 
inplantation.  Mice were given either 1U of 
elastase (broken line) or PBS (solid line) 
which was incubated in-vivo overnight.  
100mg/ml of  a fluorescently labelled 40KDa 
dextran was added to each chamber and 
each chamber was sampled periodically for 
6 hours.  +/- sd, n=5/group 
•   The concentration of ETA & elastase within skin chambers of CP treated mice was about six to eight times higher than in skin chambers of normal 
mice infected with similar colony forming units of P.aeruginosa (Figure 1 & 5).  
•   The CP treatment reduced the leukocyte concentration, and an increase in VF concentration in the chamber was observed (Figure 2).  It is likely 
that the increased VF concentration was caused by the reduced number of leukocytes in the chamber. 
•   Elastase treatment resulted in vascular permeability indicated by a decrease in dextran marker concentration (Figure 6),  an increase in exudate 
volume in the chamber (Figure 7), and increased the influx of RBCs. 
•   Collectively, these results support our hypothesis that the increased concentration of VFs is responsible for the progression of P.aeruginosa from 
dermal infection to septicaemia. 
Conclusions 
